Pharma BD Deal Intelligence
A platform licensing deal worth up to $3B that gave J&J access to Genmab's DuoBody bispecific technology. The partnership produced teclistamab (Tecvayli) for multiple myeloma and a pipeline of bispecific programs—positioning J&J beyond checkpoint inhibitors.
Genmab enters broad collaboration with Janssen Biotech for DuoBody platform to create bispecific antibodies with up to $175 million per product in milestones.
Janssen Biotech announced a global license and development agreement with Genmab for daratumumab, paying $55 million upfront plus an $80 million equity…
Janssen and Genmab expanded their partnership with a follow-on to Darzalex for multiple myeloma and diffuse large B-cell lymphoma, demonstrating the continued…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Janssen licensed Genmab's DuoBody bispecific antibody platform, leading to development of teclistamab (Tecvayli) and other bispecific programs in oncology.
35K US cases/yr · $10.0B Global Multiple Myeloma Market (2015)
Multiple myeloma is a hematologic malignancy of plasma cells, the second most common blood cancer. In 2012, treatment was evolving rapidly with proteasome inhibitors (Velcade) and immunomodulators (Revlimid) as backbone therapies, but relapsed/refractory patients had limited options. Bispecific antibodies targeting BCMA were an emerging modality.
At deal signing (2012), the MM landscape was dominated by Celgene (Revlimid, Pomalyst), J&J/Takeda (Velcade), and emerging anti-CD38 antibodies (daratumumab). Genmab's DuoBody platform for bispecific T-cell engagers was pre-clinical but represented a next-generation approach. Teclistamab (BCMAxCD3) ultimately gained FDA approval in 2022, validating the $3B+ platform bet.
Janssen licensed DuoBody bispecific antibody platform from Genmab for oncology development.
FDA accelerated approval for teclistamab in r/r multiple myeloma. First BCMAxCD3 bispecific.
Tecvayli approved in US, EU, Japan. DuoBody platform produced second approved therapy. Mid-single digit royalties to Genmab.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Genmab A/S (this deal) | 2012 | $3.0B | 77 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2012 deals · Johnson & Johnson deals · Oncology deals